14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ODV vs RNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Osisko Development Corp. (ODV) is the stronger overall head-to-head candidate over Avidity Biosciences, Inc. (RNA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ODV carries a Unified Composite Score of 56.2/100 (HOLD) at $2.27 (24.0x Forward P/E, -414.1% operating margin), whereas RNA carries 41.9/100 (SELL) at $6.43 (N/M Forward P/E, -194.8% operating margin).
Technical & Structure Timing Caution: ODV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile RNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ODV vs RNA. Trailing 12-month operating profitability (ODV -414.1% vs RNA -194.8%) and valuation multiples (ODV 24.0x vs RNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $162.0M market capitalization and -194.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ODV vs RNA Key Questions & Quantitative Answers
As of Nov 16, 2026, Osisko Development Corp. (ODV) is the stronger overall head-to-head candidate over Avidity Biosciences, Inc. (RNA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ODV carries a Unified Composite Score of 56.2/100 (HOLD) at $2.27 (24.0x Forward P/E, -414.1% operating margin), whereas RNA carries 41.9/100 (SELL) at $6.43 (N/M Forward P/E, -194.8% operating margin). Technical & Structure Timing Caution: ODV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile RNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ODV leads the Growth & Scale pillar: ODV posts +2638.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (61.5% gross margin, -414.1% operating margin), compared with RNA at +24.2% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-14.0% gross margin, -194.8% operating margin). On trailing 12-month operating scale, ODV generates $38M in USD-normalized revenue versus $39M for RNA. In operating R&D and SG&A reinvestment, ODV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RNA.
ODV screens cheaper on headline valuation multiples. ODV trades at 24.0x Forward P/E, 24.0x Trailing P/E, N/M PEG, and 18.0x EV/Revenue (-114.9% EBITDA margin), whereas RNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ODV (-12.4% ROE) versus RNA (-95.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ODV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.13β · 45% Vol realized risk). By comparison, RNA carries 0.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.